Alzheimer's Med Seems Ineffective in Those With Down
TUESDAY, Jan. 10 (HealthDay News) -- A drug commonly used to
treat patients with Alzheimer's disease does not appear to be
effective for people older than 40 years who have Down syndrome and
Alzheimer's, according to a new study.
Although previous animal studies of the Alzheimer's drug,
memantine, showed promising results in mice with Down syndrome,
this new study of people with Down syndrome aged 40 and older
revealed the opposite, the researchers reported in the Jan. 9
online edition of
Memantine was given to 88 people with Down syndrome for one
year, while another 85 patients received a placebo (the "control"
group). Some of the participants had Alzheimer's and some
The investigators found that the brain function of the people in
both groups declined equally.
Serious adverse effects were experienced by 11 percent of the
group that took the medication. Meanwhile, 7 percent of the placebo
group had similar adverse events. Five people from the medication
group died because of these events, compared to four in the control
"Memantine is not an effective treatment in this group of patients. We believe that this robust finding will have implications for clinical practice and research strategy in the future. Specifically, therapies that are beneficial for people with Alzheimer's disease are not necessarily effective for the treatment of cognitive impairment or dementia in the context of Down syndrome," the study's author, Clive Ballard, a professor at the Wolfson Centre for Age-Related Diseases at King's College London, said in a journal news release.
Because nearly 40 percent of people with Down syndrome over 60
years of age are diagnosed with dementia, the study authors pointed
out that more research is needed to determine the best way to treat
dementia in these individuals.
"Further investment is urgently needed to develop treatments that are effective in this important group of people," the study's co-author, Anne Corbett, research manager at Alzheimer's Society (U.K.), stated in the news release.
The U.S. National Institute of Neurological Disorders and Stroke
provides more information on
Copyright © 2012
. All rights reserved.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.